Advertisement

Chemo Fog pp 21-25 | Cite as

The Impact of Chemo Brain on the Patient with a High-Grade Glioma

  • Michele R. Lucas
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 678)

Abstract

Health-related quality of life for patients with high-grade gliomas has always been poor. The multiple insults to the brain—tumor existence and surgical procedures, irradiation, the level of stress and anxiety suffered and the adjuvant medications— steroids and anti-convulsants, all combine to diminish their health-related quality of life. Prior to the development of chemotherapy agents capable of penetrating the blood brain barrier, prognosis was 6 to 18 months. Life expectancy was short and there was little time to address the health-related quality of life. The newer agents have served to extend life, but have added another condition to the existing poor health-related quality of life, i.e., chemo brain. Chemo brain affects all cognitive function. The patients have great difficulty processing information. They have reduced attentional and concentration capability and cannot learn new information. The overall impact on their lives renders them unemployable and places a great burden on their families and on society. This chapter provides an overview of the patient experience and the burden placed on their families and on society.

Keywords

Malignant Glioma Family Unit Brainstem Glioma Healthy Brain Tissue Optic Nerve Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Correa DD, Ahles TA. Neurocognitive changes in cancer patients. Cancer J 2008; 14(6):396–400.PubMedCrossRefGoogle Scholar
  2. 2.
    Dietrich Jorg, Monte M, Wefel J et al. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13:1–11.Google Scholar
  3. 3.
    Fox S, Lantz C. The brain tumor experience and quality of life: a qualitative study. J Neurosci Nurs 1998; 30:245–255.PubMedCrossRefGoogle Scholar
  4. 4.
    Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 2007; 39(1):61–67.PubMedCrossRefGoogle Scholar
  5. 5.
    Hahn CA, Dunn RH, Logue PE et al. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 2003; 55(4):992–999.PubMedCrossRefGoogle Scholar
  6. 6.
    Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum 2007; 34(5):981–994.PubMedCrossRefGoogle Scholar
  7. 7.
    Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: Effects, potential mechanisms and management. Am J Ther 2006; 13:362–369.PubMedCrossRefGoogle Scholar
  8. 8.
    Kipnis J, Derecki NC, Yang C et al. Immunity and cognition: what do age-related dementia, HIV-dementia and ‘chemo-brain’ have in common? Cell 2008; 455–463.Google Scholar
  9. 9.
    Mauer ME, Bottomley A, Taphoon MJB. Evaluating health-related quality of life and symptom burden in brain tumor patients: instruments for use in experimental trials and clinical practice. Curr Opin in Neurol 2008; 21:745–753.CrossRefGoogle Scholar
  10. 10.
    Munoz C, Juarez G, Munoz M et al. The quality of life of patients with malignant gliomas and their caregivers. Soc Work Health Care 2008; 47(4):455–478.PubMedCrossRefGoogle Scholar
  11. 11.
    Raffa RB, Duong PV, Finney J et al. Is ‘chemo-fog’/‘chemo-brain’ caused by cancer chemotherapy? J Clin Pharm Ther 2006; 31:129–138.PubMedCrossRefGoogle Scholar
  12. 12.
    Remer S, Murphy ME. The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin J Oncol Nurs 2004; 8(4):368–376.PubMedCrossRefGoogle Scholar
  13. 13.
    Staat K, Segatore M. The phenomenon of chemo brain. Clin J Oncol Nurs 2005; 9(6):713–721.PubMedCrossRefGoogle Scholar
  14. 14.
    Taphoon MJB, Klein M. Cognitive deficits in adult patients with brain tumors. Lancet Neurol 2004; 3:159–168.CrossRefGoogle Scholar
  15. 15.
    Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. American Cancer Society; 2004; online: 2292–2299.Google Scholar
  16. 16.
    Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psycho-oncology 1997; 6:169–177.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Michele R. Lucas
    • 1
  1. 1.Stephen E. and Catherine Pappas Center for Neuro-OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations